JP2020090520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020090520A5 JP2020090520A5 JP2020013314A JP2020013314A JP2020090520A5 JP 2020090520 A5 JP2020090520 A5 JP 2020090520A5 JP 2020013314 A JP2020013314 A JP 2020013314A JP 2020013314 A JP2020013314 A JP 2020013314A JP 2020090520 A5 JP2020090520 A5 JP 2020090520A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- group
- cancer
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 114
- -1 1-imidazolyl Chemical group 0.000 claims 88
- 206010028980 Neoplasm Diseases 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 22
- 206010039491 Sarcoma Diseases 0.000 claims 21
- 125000003282 alkyl amino group Chemical group 0.000 claims 21
- 125000004663 dialkyl amino group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 208000032839 leukemia Diseases 0.000 claims 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 201000009030 Carcinoma Diseases 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 150000003857 carboxamides Chemical class 0.000 claims 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 208000007538 neurilemmoma Diseases 0.000 claims 4
- 206010039667 schwannoma Diseases 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 3
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 208000009956 adenocarcinoma Diseases 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000000762 glandular Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 2
- KOFIDSXHWGFEMO-UHFFFAOYSA-N 1-(2-methylpropyl)pyrrolidine Chemical compound CC(C)CN1CCCC1 KOFIDSXHWGFEMO-UHFFFAOYSA-N 0.000 claims 2
- MCMFEZDRQOJKMN-UHFFFAOYSA-N 1-butylimidazole Chemical compound CCCCN1C=CN=C1 MCMFEZDRQOJKMN-UHFFFAOYSA-N 0.000 claims 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 2
- QVTTWNXAJRQQHZ-UHFFFAOYSA-N 5-prop-1-enyl-1h-imidazole Chemical compound CC=CC1=CN=CN1 QVTTWNXAJRQQHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 2
- 241000234671 Ananas Species 0.000 claims 2
- 235000007119 Ananas comosus Nutrition 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- VQLOEDJRIKSWII-UHFFFAOYSA-N ClC1=CC=C(CN2N=CC(=C2)CN2CC(C2)NC(=O)C=2N=NC=C(C=2)C2CC2)C=C1 Chemical compound ClC1=CC=C(CN2N=CC(=C2)CN2CC(C2)NC(=O)C=2N=NC=C(C=2)C2CC2)C=C1 VQLOEDJRIKSWII-UHFFFAOYSA-N 0.000 claims 2
- MOWCUCXGYVJUHU-UHFFFAOYSA-N ClC1=CC=C(CN2N=CC(=C2)CN2CC(C2)NC(=O)C=2N=NN(C=2)C2CC2)C=C1 Chemical compound ClC1=CC=C(CN2N=CC(=C2)CN2CC(C2)NC(=O)C=2N=NN(C=2)C2CC2)C=C1 MOWCUCXGYVJUHU-UHFFFAOYSA-N 0.000 claims 2
- FAONROFAUHXDEW-UHFFFAOYSA-N ClC1=CC=C(CN2N=CC(=C2)CN2CC(C2)NC(=O)C=2NC=C(N=2)C2CC2)C=C1 Chemical compound ClC1=CC=C(CN2N=CC(=C2)CN2CC(C2)NC(=O)C=2NC=C(N=2)C2CC2)C=C1 FAONROFAUHXDEW-UHFFFAOYSA-N 0.000 claims 2
- MMWPQYHOBAXYAX-UHFFFAOYSA-N ClC1=CC=C(CN2N=CC(=C2)CN2CC(C2)NC(C2=NC=CC(=C2)C2CC2)=O)C=C1 Chemical compound ClC1=CC=C(CN2N=CC(=C2)CN2CC(C2)NC(C2=NC=CC(=C2)C2CC2)=O)C=C1 MMWPQYHOBAXYAX-UHFFFAOYSA-N 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 2
- INSSHDIMRIMVLZ-UHFFFAOYSA-N butan-2-ylcyclopropane Chemical compound CCC(C)C1CC1 INSSHDIMRIMVLZ-UHFFFAOYSA-N 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000002308 embryonic cell Anatomy 0.000 claims 2
- 206010016629 fibroma Diseases 0.000 claims 2
- 230000003325 follicular Effects 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000005191 hydroxyalkylamino group Chemical group 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 206010024627 liposarcoma Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 2
- NPUKKLNOJTXUGO-UHFFFAOYSA-N n-[1-(4-acetamidophenyl)sulfonylpiperidin-4-yl]benzamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)N1CCC(NC(=O)C=2C=CC=CC=2)CC1 NPUKKLNOJTXUGO-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 claims 1
- XXBQLHATYQHJQC-UHFFFAOYSA-N 1,2-dihydroquinoxaline Chemical compound C1=CC=C2N=CCNC2=C1 XXBQLHATYQHJQC-UHFFFAOYSA-N 0.000 claims 1
- HYTIPJFUWHYQON-UHFFFAOYSA-N 3,4-dihydro-1h-quinoxalin-2-one Chemical compound C1=CC=C2NC(=O)CNC2=C1 HYTIPJFUWHYQON-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000007690 Brenner tumor Diseases 0.000 claims 1
- 206010073258 Brenner tumour Diseases 0.000 claims 1
- 206010070487 Brown tumour Diseases 0.000 claims 1
- 208000009458 Carcinoma in Situ Diseases 0.000 claims 1
- 201000000274 Carcinosarcoma Diseases 0.000 claims 1
- 208000007389 Cementoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010008583 Chloroma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 claims 1
- 208000033832 Eosinophilic Acute Leukemia Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010018404 Glucagonoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061872 Non-renal cell carcinoma of kidney Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 201000010630 Pancoast tumor Diseases 0.000 claims 1
- 208000015330 Pancoast tumour Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000034541 Rare lymphatic malformation Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000033889 Renal medullary carcinoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000025316 Richter syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 206010041329 Somatostatinoma Diseases 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 claims 1
- 208000005310 acidophil adenoma Diseases 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 201000005179 adrenal carcinoma Diseases 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 210000004252 chorionic villi Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 210000003298 dental enamel Anatomy 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 208000037902 enteropathy Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000000416 exudates and transudate Anatomy 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000002149 gonad Anatomy 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 208000006359 hepatoblastoma Diseases 0.000 claims 1
- 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 201000004933 in situ carcinoma Diseases 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000020319 kidney medullary carcinoma Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 1
- 208000015179 malignant superior sulcus neoplasm Diseases 0.000 claims 1
- 201000001117 malignant triton tumor Diseases 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 208000029586 mediastinal germ cell tumor Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000022669 mucinous neoplasm Diseases 0.000 claims 1
- 201000005987 myeloid sarcoma Diseases 0.000 claims 1
- 208000017708 myomatous neoplasm Diseases 0.000 claims 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims 1
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 208000027500 optic nerve neoplasm Diseases 0.000 claims 1
- 208000022982 optic pathway glioma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 208000023974 pharynx neoplasm Diseases 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 208000024246 polyembryoma Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 201000007363 trachea carcinoma Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000025443 tumor of adipose tissue Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 208000037964 urogenital cancer Diseases 0.000 claims 1
- 208000023747 urothelial carcinoma Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022118248A JP2022163087A (ja) | 2014-09-10 | 2022-07-25 | Ｓｍｙｄ阻害剤 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048773P | 2014-09-10 | 2014-09-10 | |
| US62/048,773 | 2014-09-10 | ||
| US201562146799P | 2015-04-13 | 2015-04-13 | |
| US62/146,799 | 2015-04-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512982A Division JP2017538659A (ja) | 2014-09-10 | 2015-09-09 | Ｓｍｙｄ阻害剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022118248A Division JP2022163087A (ja) | 2014-09-10 | 2022-07-25 | Ｓｍｙｄ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020090520A JP2020090520A (ja) | 2020-06-11 |
| JP2020090520A5 true JP2020090520A5 (enExample) | 2020-12-10 |
Family
ID=55459528
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512982A Pending JP2017538659A (ja) | 2014-09-10 | 2015-09-09 | Ｓｍｙｄ阻害剤 |
| JP2020013314A Pending JP2020090520A (ja) | 2014-09-10 | 2020-01-30 | Ｓｍｙｄ阻害剤 |
| JP2022118248A Pending JP2022163087A (ja) | 2014-09-10 | 2022-07-25 | Ｓｍｙｄ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512982A Pending JP2017538659A (ja) | 2014-09-10 | 2015-09-09 | Ｓｍｙｄ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022118248A Pending JP2022163087A (ja) | 2014-09-10 | 2022-07-25 | Ｓｍｙｄ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10266526B2 (enExample) |
| EP (1) | EP3193600A4 (enExample) |
| JP (3) | JP2017538659A (enExample) |
| KR (2) | KR102496364B1 (enExample) |
| CN (2) | CN107072205B (enExample) |
| AU (1) | AU2015315174B2 (enExample) |
| BR (1) | BR112017004612A2 (enExample) |
| CA (1) | CA2960275A1 (enExample) |
| EA (1) | EA201790317A1 (enExample) |
| IL (2) | IL250891A0 (enExample) |
| MX (2) | MX2017002985A (enExample) |
| SG (2) | SG10201901192TA (enExample) |
| WO (1) | WO2016040505A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| PT3131582T (pt) | 2014-04-15 | 2018-10-08 | Vertex Pharma | Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística |
| MX2017002986A (es) | 2014-09-10 | 2017-10-24 | Epizyme Inc | Compuestos de piperidina sustituidos. |
| JP2017526706A (ja) | 2014-09-10 | 2017-09-14 | エピザイム，インコーポレイティド | イソオキサゾールカルボキサミド化合物 |
| JP2017528460A (ja) | 2014-09-10 | 2017-09-28 | エピザイム インコーポレイテッド | 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド |
| AU2015315171A1 (en) | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Substituted cyclohexylamine compounds |
| WO2018030550A1 (en) | 2016-08-09 | 2018-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds with an ror(gamma)t modulating activity |
| WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
| AU2018231120B2 (en) * | 2017-03-10 | 2022-06-23 | Rutgers, The State University Of New Jersey | Indole derivatives as efflux pump inhibitors |
| US20200138827A1 (en) * | 2017-06-22 | 2020-05-07 | Curadev Pharma Limited | Small molecule modulators of human sting |
| AU2018288018C1 (en) | 2017-06-22 | 2022-10-20 | Curadev Pharma Limited | Small molecule modulators of human STING |
| CA3072746A1 (en) | 2017-08-14 | 2019-02-21 | Epizyme, Inc. | Methods of treating cancer by inhibiting setd2 |
| EP3837240A4 (en) * | 2018-08-14 | 2022-04-27 | Epizyme, Inc. | Substituted indoles and methods of use thereof |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| DK3873884T3 (da) | 2018-10-30 | 2025-02-17 | Gilead Sciences Inc | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme |
| EP3873897B1 (en) | 2018-10-30 | 2024-08-14 | Gilead Sciences, Inc. | N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases |
| PL3873605T3 (pl) | 2018-10-30 | 2025-03-03 | Gilead Sciences, Inc. | Związki hamujące integrynę alfa4beta7 |
| EP4010341A1 (en) * | 2019-08-08 | 2022-06-15 | Université de Strasbourg | Trkb positive allosteric modulators |
| US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| WO2021134004A1 (en) * | 2019-12-27 | 2021-07-01 | Schrodinger, Inc. | Cyclic compounds and methods of using same |
| US20230133671A1 (en) * | 2020-02-19 | 2023-05-04 | Epizyme, Inc. | Setd2 inhibitors and related methods and uses, including combination therapies |
| WO2021257544A1 (en) | 2020-06-16 | 2021-12-23 | Icahn School Of Medicine At Mount Sinai | Sox11 inhibitors for treating mantle cell lymphoma |
| EP4263535A1 (en) | 2020-12-17 | 2023-10-25 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| CN114246851B (zh) * | 2021-11-09 | 2024-01-26 | 澳门科技大学 | 一种组蛋白甲基转移酶smyd3小分子抑制剂的合成方法及用途 |
| CN114702552B (zh) * | 2022-03-11 | 2024-05-31 | 苏州思萃免疫技术研究所有限公司 | mTORC2抑制剂 |
| WO2023192665A2 (en) * | 2022-04-01 | 2023-10-05 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| GB2620976B (en) * | 2022-07-28 | 2024-07-24 | Jones Paul | Amido-amine hardener |
| CN120981228A (zh) * | 2022-11-17 | 2025-11-18 | 腾维治疗公司 | 化合物、组合物和方法 |
| CN120882411A (zh) * | 2022-11-17 | 2025-10-31 | 腾维治疗公司 | 化合物、组合物和方法 |
| WO2024158863A1 (en) * | 2023-01-25 | 2024-08-02 | The Rockefeller University | Sulfonamide-1h-pyrrole-2-carboxamide inhibitors of sars-cov-2 nsp14 methyltransferase and derivatives thereof |
| CN116327748B (zh) * | 2023-04-21 | 2024-09-17 | 武汉科技大学 | 联合用药物在制备抗肿瘤药物中的用途 |
| WO2025165834A1 (en) * | 2024-01-31 | 2025-08-07 | Ensem Therapeutics, Inc. | Urea derivatives of tricyclic compounds, and compositions and methods thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1441195A (en) * | 1993-12-30 | 1995-07-17 | Smithkline Beecham Corporation | Phenylmethyl hexanamides, and the use thereof |
| WO1998022432A1 (en) * | 1996-11-18 | 1998-05-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same |
| CZ20021009A3 (cs) * | 1999-09-21 | 2002-06-12 | Astrazeneca Ab | Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv |
| US6867299B2 (en) * | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
| TWI290136B (en) * | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
| CA2415961A1 (en) | 2000-07-19 | 2002-01-24 | Hirohiko Nishiyama | Production method of 1-substituted-1,2,3-triazole derivatives |
| AUPR034000A0 (en) * | 2000-09-25 | 2000-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
| AU2002338334B8 (en) * | 2001-04-03 | 2008-09-18 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists |
| EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| GB0205176D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| JP2004175739A (ja) * | 2002-11-28 | 2004-06-24 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JP2004315395A (ja) * | 2003-04-14 | 2004-11-11 | Yamanouchi Pharmaceut Co Ltd | 新規な安息香酸誘導体又はその塩 |
| GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| CA2538759C (en) * | 2003-09-12 | 2015-11-03 | Elixir Pharmaceuticals, Inc. | Substituted heterocyclic compounds as sirtuin inhitibitors |
| JP2007518823A (ja) * | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途 |
| EP1718611A4 (en) * | 2004-02-13 | 2009-09-23 | Harvard College | 3-3-DI-SUBSTITUTED OXINDOLES AS INHIBITORS OF INITIATION OF TRANSLATION |
| JP2006089485A (ja) * | 2004-08-24 | 2006-04-06 | Santen Pharmaceut Co Ltd | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| CA2588607A1 (en) * | 2004-11-23 | 2006-06-01 | Ptc Therapeutics, Inc. | Carbazole, carboline and indole derivatives useful in the inhibition of vegf production |
| US20090253671A1 (en) * | 2005-03-04 | 2009-10-08 | Astrazeneca Ab | Tricyclic derivatives of azetidine and pyrrole with antibacterial activity |
| AU2006232620A1 (en) * | 2005-04-06 | 2006-10-12 | Astrazeneca Ab | Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors |
| WO2007002220A2 (en) * | 2005-06-21 | 2007-01-04 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as beta-secretase inhibitors |
| TW200741009A (en) * | 2005-07-01 | 2007-11-01 | Oncotherapy Science Inc | Methods of modulating SMYD3 for treatment of cancer |
| PE20071092A1 (es) * | 2005-12-08 | 2007-12-10 | Aventis Pharma Inc | Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico |
| GB0525083D0 (en) * | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| US7838542B2 (en) * | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
| EP2043634A2 (en) * | 2006-07-12 | 2009-04-08 | Merck & Co., Inc. | Substituted pyrazoles as ghrelin receptor antagonists |
| WO2008016666A2 (en) * | 2006-08-02 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| JP2010513263A (ja) * | 2006-12-15 | 2010-04-30 | ファイザー・プロダクツ・インク | ベンズイミダゾール誘導体 |
| CA2672373C (en) * | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| PE20091576A1 (es) * | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
| WO2009143039A2 (en) * | 2008-05-19 | 2009-11-26 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| TW201010997A (en) | 2008-06-18 | 2010-03-16 | Pfizer Ltd | Nicotinamide derivatives |
| ES2620027T3 (es) * | 2008-09-03 | 2017-06-27 | Biomarin Pharmaceutical Inc. | Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC |
| WO2012050393A2 (ko) * | 2010-10-14 | 2012-04-19 | 제이더블유중외제약 주식회사 | 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 |
| CA2820035A1 (en) * | 2010-12-08 | 2012-06-14 | Lycera Corporation | Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
| WO2012135697A2 (en) * | 2011-03-30 | 2012-10-04 | H. Lee Moffitt Cancer Center & Research Institute Inc. | Novel rho kinase inhibitors and methods of use |
| EP2532661A1 (en) * | 2011-06-10 | 2012-12-12 | Syngenta Participations AG | Novel insecticides |
| CN103635474B (zh) * | 2011-06-17 | 2016-04-27 | 巴斯利尔药物股份公司 | 三环抗生素 |
| US9145412B2 (en) * | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| CN103877078B (zh) * | 2012-12-20 | 2017-03-15 | 上海交通大学医学院 | Senp2小分子抑制剂及其应用 |
| JP2017526706A (ja) | 2014-09-10 | 2017-09-14 | エピザイム，インコーポレイティド | イソオキサゾールカルボキサミド化合物 |
| US20170247326A1 (en) | 2014-09-10 | 2017-08-31 | Epizyme, Inc. | Substituted Pyrrolidine Carboxamide Compounds |
| AU2015315171A1 (en) | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Substituted cyclohexylamine compounds |
| MX2017002986A (es) | 2014-09-10 | 2017-10-24 | Epizyme Inc | Compuestos de piperidina sustituidos. |
| JP2017528460A (ja) | 2014-09-10 | 2017-09-28 | エピザイム インコーポレイテッド | 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド |
| US20170253601A1 (en) | 2014-09-10 | 2017-09-07 | Epizyme, Inc. | Substituted Pyrrolidine Compounds |
-
2015
- 2015-09-09 KR KR1020177009602A patent/KR102496364B1/ko active Active
- 2015-09-09 MX MX2017002985A patent/MX2017002985A/es unknown
- 2015-09-09 CA CA2960275A patent/CA2960275A1/en active Pending
- 2015-09-09 BR BR112017004612-1A patent/BR112017004612A2/pt not_active Application Discontinuation
- 2015-09-09 EA EA201790317A patent/EA201790317A1/ru unknown
- 2015-09-09 WO PCT/US2015/049221 patent/WO2016040505A1/en not_active Ceased
- 2015-09-09 CN CN201580060859.4A patent/CN107072205B/zh not_active Expired - Fee Related
- 2015-09-09 SG SG10201901192TA patent/SG10201901192TA/en unknown
- 2015-09-09 US US15/510,586 patent/US10266526B2/en active Active
- 2015-09-09 CN CN202210734932.3A patent/CN115028619A/zh active Pending
- 2015-09-09 JP JP2017512982A patent/JP2017538659A/ja active Pending
- 2015-09-09 AU AU2015315174A patent/AU2015315174B2/en not_active Ceased
- 2015-09-09 EP EP15840789.0A patent/EP3193600A4/en not_active Withdrawn
- 2015-09-09 KR KR1020237003762A patent/KR20230026515A/ko not_active Ceased
- 2015-09-09 SG SG11201701598PA patent/SG11201701598PA/en unknown
-
2017
- 2017-03-02 IL IL250891A patent/IL250891A0/en unknown
- 2017-03-07 MX MX2023006257A patent/MX2023006257A/es unknown
-
2019
- 2019-02-06 US US16/269,338 patent/US20190322660A1/en not_active Abandoned
-
2020
- 2020-01-30 JP JP2020013314A patent/JP2020090520A/ja active Pending
- 2020-05-01 US US16/864,891 patent/US20210198252A1/en not_active Abandoned
-
2021
- 2021-10-10 IL IL287113A patent/IL287113A/en unknown
- 2021-11-22 US US17/532,422 patent/US20230101819A1/en not_active Abandoned
-
2022
- 2022-07-25 JP JP2022118248A patent/JP2022163087A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020090520A5 (enExample) | ||
| JP2017538659A5 (enExample) | ||
| TWI816962B (zh) | Mat2a之雜雙環抑制劑及用於治療癌症之使用方法 | |
| DK3087070T3 (en) | PYRAZOLO [1,5-A] PYRIDINE DERIVATIVES AND PROCEDURES FOR THEIR USE | |
| US7795440B2 (en) | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | |
| US8536168B2 (en) | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | |
| EP2207773B1 (en) | Heterocyclic compound and pharmaceutical composition thereof | |
| US20180201610A1 (en) | Compositions and methods of targeting mutant k-ras | |
| JP2011510995A5 (enExample) | ||
| KR20010031908A (ko) | 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체 | |
| WO2013074633A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| US20130225581A1 (en) | Nitrogen-containing aromatic heterocyclic derivative | |
| MXPA05007990A (es) | Compuestos de tienopirimidina y uso de los mismos. | |
| KR20030036686A (ko) | Ｖｅｇｆ 억제 활성이 있는 퀴놀린 유도체 | |
| JP2017528461A5 (enExample) | ||
| CA2899968A1 (en) | Substituted 2-aminopyridine protein kinase inhibitor | |
| US20250179013A1 (en) | Inhibitors of rna helicase dhx9 and uses thereof | |
| AU2014284013B2 (en) | Five-membered heterocyclic pyridine compounds and preparation method and use thereof | |
| KR20180073681A (ko) | 1,4-디카르보닐-피페리딜 유도체 | |
| CN115279759B (zh) | 苯甲酰胺衍生物及其制备方法和用途 | |
| KR20150047609A (ko) | 피리딘 유도체 및 의약 | |
| US20210395225A1 (en) | Functionalized aminotriazines | |
| AU2014200824B2 (en) | Substituted triazoles useful as Axl inhibitors | |
| MXPA00004491A (en) | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | |
| AU2016259396A1 (en) | Substituted triazoles useful as Axl inhibitors |